Corcept Therapeutics (CORT) Consolidated Net Income (2010 - 2026)

Corcept Therapeutics has disclosed Consolidated Net Income across 17 years of filings, most recently posting -$31.8 million for Q1 2026.

• Consolidated Net Income for Q1 2026 came in at -$31.8 million, down 254.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.3 million (down 64.67% YoY), and the FY2025 annual result was $99.7 million, down 29.43% from the prior year.
• Consolidated Net Income came in at -$31.8 million for Q1 2026 at Corcept Therapeutics, down from $24.3 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $47.2 million in Q3 2024 to a low of -$31.8 million in Q1 2026.
• The 5-year median for Consolidated Net Income is $27.5 million (2023), against an average of $24.5 million.
• Across the five-year window, Consolidated Net Income jumped 89.07% in 2023 and sank 254.8% in 2026, its largest moves.
• Corcept Therapeutics' Consolidated Net Income stood at $16.6 million in 2022, then soared by 89.07% to $31.4 million in 2023, then retreated by 2.06% to $30.7 million in 2024, then fell by 21.0% to $24.3 million in 2025, then plunged by 230.77% to -$31.8 million in 2026.
• The last three Consolidated Net Income figures came in at -$31.8 million (Q1 2026), $24.3 million (Q4 2025), and $19.7 million (Q3 2025), per Business Quant data.